{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:45:51Z","timestamp":1794573951889,"version":"4.9.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"7952","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2023,3,16]]},"DOI":"10.1038\/s41586-023-05778-2","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T12:03:24Z","timestamp":1678277004000},"page":"507-516","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":345,"title":["Co-opting signalling molecules enables logic-gated control of CAR T cells"],"prefix":"10.1038","volume":"615","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3286-0238","authenticated-orcid":false,"given":"Aidan M.","family":"Tousley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Caterina","family":"Rotiroti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louai","family":"Labanieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea Wenting","family":"Rysavy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1800-0485","authenticated-orcid":false,"given":"Won-Ju","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4179-4807","authenticated-orcid":false,"given":"Caleb","family":"Lareau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3993-1932","authenticated-orcid":false,"given":"Elena","family":"Sotillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan W.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler P.","family":"Rietberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo Nicolas","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2220-005X","authenticated-orcid":false,"given":"Yajie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Klysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"de la Serna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6096-4600","authenticated-orcid":false,"given":"Alexander R.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5167-537X","authenticated-orcid":false,"given":"Ansuman T.","family":"Satpathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6323-4304","authenticated-orcid":false,"given":"Crystal L.","family":"Mackall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6969-8011","authenticated-orcid":false,"given":"Robbie G.","family":"Majzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"5778_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. & Mackall, C. L. Clinical lessons learned from the first leg of the CAR T cell journey. Nat. Med. 25, 1341\u20131355 (2019).","journal-title":"Nat. Med."},{"key":"5778_CR2","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"5778_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71\u201375 (2013).","journal-title":"Nat. Biotechnol."},{"key":"5778_CR4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.cell.2016.09.011","volume":"167","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic Notch receptors. Cell 167, 419\u2013432 (2016).","journal-title":"Cell"},{"key":"5778_CR5","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl Med. 5, 215ra172 (2013).","journal-title":"Sci. Transl Med."},{"key":"5778_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489\u2013503 (2019).","journal-title":"Cancer Cell"},{"key":"5778_CR7","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41577-018-0042-2","volume":"18","author":"CR Maldini","year":"2018","unstructured":"Maldini, C. R., Ellis, G. I. & Riley, J. L. CAR T cells for infection, autoimmunity and allotransplantation. Nat. Rev. Immunol. 18, 605\u2013616 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"5778_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"5778_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"RC Larson","year":"2021","unstructured":"Larson, R. C. & Maus, M. V. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat. Rev. Cancer 21, 145\u2013161 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"5778_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","volume":"10","author":"RG Majzner","year":"2020","unstructured":"Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702\u2013723 (2020).","journal-title":"Cancer Discov."},{"key":"5778_CR11","doi-asserted-by":"publisher","first-page":"eabe2606","DOI":"10.1126\/scisignal.abe2606","volume":"14","author":"AI Salter","year":"2021","unstructured":"Salter, A. I. et al. Comparative analysis of TCR and CAR signaling informs CAR designs with superior antigen sensitivity and in vivo function. Sci. Signal. 14, eabe2606 (2021).","journal-title":"Sci. Signal."},{"key":"5778_CR12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","volume":"2","author":"L Labanieh","year":"2018","unstructured":"Labanieh, L., Majzner, R. G. & Mackall, C. L. Programming CAR-T cells to kill cancer. Nat. Biomed. Eng. 2, 377\u2013391 (2018).","journal-title":"Nat. Biomed. Eng."},{"key":"5778_CR13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"5778_CR14","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar, Z., Waks, T., Gross, G. & Schindler, D. G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl Acad. Sci. USA 90, 720\u2013724 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"5778_CR15","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/0092-8674(91)90327-U","volume":"64","author":"C Romeo","year":"1991","unstructured":"Romeo, C. & Seed, B. Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides. Cell 64, 1037\u20131046 (1991).","journal-title":"Cell"},{"key":"5778_CR16","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"BA Irving","year":"1991","unstructured":"Irving, B. A. & Weiss, A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 64, 891\u2013901 (1991).","journal-title":"Cell"},{"key":"5778_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1126\/science.2371564","volume":"249","author":"SJ Frank","year":"1990","unstructured":"Frank, S. J. et al. Structural mutations of the T cell receptor zeta chain and its role in T cell activation. Science 249, 174\u2013177 (1990).","journal-title":"Science"},{"key":"5778_CR18","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","volume":"161","author":"HM Finney","year":"1998","unstructured":"Finney, H. M., Lawson, A. D., Bebbington, C. R. & Weir, A. N. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. 161, 2791\u20132797 (1998).","journal-title":"J. Immunol."},{"key":"5778_CR19","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","volume":"119","author":"HJ Pegram","year":"2012","unstructured":"Pegram, H. J. et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119, 4133\u20134141 (2012).","journal-title":"Blood"},{"key":"5778_CR20","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"5778_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","volume":"576","author":"RC Lynn","year":"2019","unstructured":"Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293\u2013300 (2019).","journal-title":"Nature"},{"key":"5778_CR22","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.4049\/jimmunol.0900447","volume":"183","author":"Y Zhao","year":"2009","unstructured":"Zhao, Y. et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J. Immunol. 183, 5563\u20135574 (2009).","journal-title":"J. Immunol."},{"key":"5778_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"5778_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904\u2013912 (2013).","journal-title":"Mol. Ther."},{"key":"5778_CR25","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","volume":"24","author":"CH Lamers","year":"2006","unstructured":"Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20\u2013e22 (2006).","journal-title":"J. Clin. Oncol."},{"key":"5778_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","volume":"43","author":"AH Courtney","year":"2018","unstructured":"Courtney, A. H., Lo, W. L. & Weiss, A. TCR signaling: mechanisms of initiation and propagation. Trends Biochem. Sci. 43, 108\u2013123 (2018).","journal-title":"Trends Biochem. Sci."},{"key":"5778_CR27","doi-asserted-by":"publisher","first-page":"7990","DOI":"10.1038\/sj.onc.1208074","volume":"23","author":"EH Palacios","year":"2004","unstructured":"Palacios, E. H. & Weiss, A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23, 7990\u20138000 (2004).","journal-title":"Oncogene"},{"key":"5778_CR28","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/0092-8674(92)90308-Y","volume":"70","author":"PL Stein","year":"1992","unstructured":"Stein, P. L., Lee, H. M., Rich, S. & Soriano, P. pp59fyn mutant mice display differential signaling in thymocytes and peripheral T cells. Cell 70, 741\u2013750 (1992).","journal-title":"Cell"},{"key":"5778_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/BF02897960","volume":"6","author":"K Yamakami","year":"2001","unstructured":"Yamakami, K., Akao, S., Wakabayashi, K., Tadakuma, T. & Yoshizawa, N. Mice lacking protein tyrosine kinase fyn develop a T helper-type 1 response and resist Leishmania major infection. Environ. Health Prev. Med. 6, 132\u2013135 (2001).","journal-title":"Environ. Health Prev. Med."},{"key":"5778_CR30","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1182\/blood.V75.7.1531.1531","volume":"75","author":"JA Ledbetter","year":"1990","unstructured":"Ledbetter, J. A. et al. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 75, 1531\u20131539 (1990).","journal-title":"Blood"},{"key":"5778_CR31","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1128\/MCB.19.1.948","volume":"19","author":"Q Zhao","year":"1999","unstructured":"Zhao, Q., Williams, B. L., Abraham, R. T. & Weiss, A. Interdomain B in ZAP-70 regulates but is not required for ZAP-70 signaling function in lymphocytes. Mol. Cell. Biol. 19, 948\u2013956 (1999).","journal-title":"Mol. Cell. Biol."},{"key":"5778_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long, A. H. et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat. Med. 21, 581\u2013590 (2015).","journal-title":"Nat. Med."},{"key":"5778_CR33","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560\u20132574 (2019).","journal-title":"Clin. Cancer Res."},{"key":"5778_CR34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/nbt0102-70","volume":"20","author":"J Maher","year":"2002","unstructured":"Maher, J., Brentjens, R. J., Gunset, G., Riviere, I. & Sadelain, M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR\u03b6\/CD28 receptor. Nat. Biotechnol. 20, 70\u201375 (2002).","journal-title":"Nat. Biotechnol."},{"key":"5778_CR35","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.161.6.2888","volume":"161","author":"T Sugawara","year":"1998","unstructured":"Sugawara, T. et al. An improved retroviral gene transfer technique demonstrates inhibition of CD4\u2212CD8\u2212 thymocyte development by kinase-inactive ZAP-70. J. Immunol. 161, 2888\u20132894 (1998).","journal-title":"J. Immunol."},{"key":"5778_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1146\/annurev-immunol-042617-053335","volume":"36","author":"BB Au-Yeung","year":"2018","unstructured":"Au-Yeung, B. B., Shah, N. H., Shen, L. & Weiss, A. ZAP-70 in signaling, biology, and disease. Annu. Rev. Immunol. 36, 127\u2013156 (2018).","journal-title":"Annu. Rev. Immunol."},{"key":"5778_CR37","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1042\/bj3560461","volume":"356","author":"PE Paz","year":"2001","unstructured":"Paz, P. E. et al. Mapping the Zap-70 phosphorylation sites on LAT (linker for activation of T cells) required for recruitment and activation of signalling proteins in T cells. Biochem. J 356, 461\u2013471 (2001).","journal-title":"Biochem. J"},{"key":"5778_CR38","doi-asserted-by":"publisher","first-page":"23355","DOI":"10.1074\/jbc.M000404200","volume":"275","author":"W Zhang","year":"2000","unstructured":"Zhang, W. et al. Association of Grb2, Gads, and phospholipase C-\u03b31 with phosphorylated LAT tyrosine residues. effect of LAT tyrosine mutations on T cell angigen receptor-mediated signaling. J. Biol. Chem. 275, 23355\u201323361 (2000).","journal-title":"J. Biol. Chem."},{"key":"5778_CR39","doi-asserted-by":"publisher","first-page":"a005512","DOI":"10.1101\/cshperspect.a005512","volume":"2","author":"L Balagopalan","year":"2010","unstructured":"Balagopalan, L., Coussens, N. P., Sherman, E., Samelson, L. E. & Sommers, C. L. The LAT story: a tale of cooperativity, coordination, and choreography. Cold Spring Harb. Perspect. Biol. 2, a005512 (2010).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"5778_CR40","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1084\/jem.183.4.1937","volume":"183","author":"DG Motto","year":"1996","unstructured":"Motto, D. G., Ross, S. E., Wu, J., Hendricks-Taylor, L. R. & Koretzky, G. A. Implication of the GRB2-associated phosphoprotein SLP-76 in T cell receptor-mediated interleukin 2 production. J. Exp. Med. 183, 1937\u20131943 (1996).","journal-title":"J. Exp. Med."},{"key":"5778_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0092-8674(00)80901-0","volume":"92","author":"W Zhang","year":"1998","unstructured":"Zhang, W., Sloan-Lancaster, J., Kitchen, J., Trible, R. P. & Samelson, L. E. LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 92, 83\u201392 (1998).","journal-title":"Cell"},{"key":"5778_CR42","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh, L. et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185, 1745\u20131763 (2022).","journal-title":"Cell"},{"key":"5778_CR43","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439\u2013448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"5778_CR44","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"5778_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"5778_CR46","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","volume":"28","author":"J Wagner","year":"2020","unstructured":"Wagner, J., Wickman, E., DeRenzo, C. & Gottschalk, S. CAR T cell therapy for solid tumors: bright future or dark reality? Mol. Ther. 28, 2320\u20132339 (2020).","journal-title":"Mol. Ther."},{"key":"5778_CR47","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","volume":"26","author":"G Fuca","year":"2020","unstructured":"Fuca, G., Reppel, L., Landoni, E., Savoldo, B. & Dotti, G. Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin. Cancer Res. 26, 2444\u20132451 (2020).","journal-title":"Clin. Cancer Res."},{"key":"5778_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17175-8","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde, M. et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat. Commun. 11, 3549 (2020).","journal-title":"Nat. Commun."},{"key":"5778_CR49","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"5778_CR50","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1126\/science.aba6527","volume":"369","author":"MJ Lajoie","year":"2020","unstructured":"Lajoie, M. J. et al. Designed protein logic to target cells with precise combinations of surface antigens. Science 369, 1637\u20131643 (2020).","journal-title":"Science"},{"key":"5778_CR51","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438 (2018).","journal-title":"Cell"},{"key":"5778_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41587-019-0329-2","volume":"38","author":"M MacKay","year":"2020","unstructured":"MacKay, M. et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat. Biotechnol. 38, 233\u2013244 (2020).","journal-title":"Nat. Biotechnol."},{"key":"5778_CR53","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/j.ccell.2021.09.016","volume":"39","author":"Y Jing","year":"2021","unstructured":"Jing, Y. et al. Expression of chimeric antigen receptor therapy targets detected by single-cell sequencing of normal cells may contribute to off-tumor toxicity. Cancer Cell 39, 1558\u20131559 (2021).","journal-title":"Cancer Cell"},{"key":"5778_CR54","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126\u2013142 (2020).","journal-title":"Cell"},{"key":"5778_CR55","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0092-8674(93)90304-9","volume":"74","author":"W Kolanus","year":"1993","unstructured":"Kolanus, W., Romeo, C. & Seed, B. T cell activation by clustered tyrosine kinases. Cell 74, 171\u2013183 (1993).","journal-title":"Cell"},{"key":"5778_CR56","doi-asserted-by":"publisher","first-page":"145","DOI":"10.4049\/jimmunol.160.1.145","volume":"160","author":"CJ Fitzer-Attas","year":"1998","unstructured":"Fitzer-Attas, C. J., Schindler, D. G., Waks, T. & Eshhar, Z. Harnessing Syk family tyrosine kinases as signaling domains for chimeric single chain of the variable domain receptors: optimal design for T cell activation. J. Immunol. 160, 145\u2013154 (1998).","journal-title":"J. Immunol."},{"key":"5778_CR57","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.cell.2007.03.039","volume":"129","author":"S Deindl","year":"2007","unstructured":"Deindl, S. et al. Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Cell 129, 735\u2013746 (2007).","journal-title":"Cell"},{"key":"5778_CR58","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1126\/science.282.5397.2263","volume":"282","author":"KM Lee","year":"1998","unstructured":"Lee, K. M. et al. Molecular basis of T cell inactivation by CTLA-4. Science 282, 2263\u20132266 (1998).","journal-title":"Science"},{"key":"5778_CR59","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nm.4441","volume":"24","author":"TJ Fry","year":"2018","unstructured":"Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20\u201328 (2018).","journal-title":"Nat. Med."},{"key":"5778_CR60","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1016\/j.ymthe.2017.06.008","volume":"25","author":"AJ Walker","year":"2017","unstructured":"Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189\u20132201 (2017).","journal-title":"Mol. Ther."},{"key":"5778_CR61","doi-asserted-by":"publisher","first-page":"e57838","DOI":"10.1371\/journal.pone.0057838","volume":"8","author":"B Jena","year":"2013","unstructured":"Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS ONE\u00a08, e57838 (2013).","journal-title":"PLoS ONE"},{"key":"5778_CR62","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/cyto.a.21015","volume":"79","author":"M Roederer","year":"2011","unstructured":"Roederer, M., Nozzi, J. L. & Nason, M. C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79, 167\u2013174 (2011).","journal-title":"Cytometry A"},{"key":"5778_CR63","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41587-020-0645-6","volume":"39","author":"CA Lareau","year":"2021","unstructured":"Lareau, C. A. et al. Massively parallel single-cell mitochondrial DNA genotyping and chromatin profiling. Nat. Biotechnol. 39, 451\u2013461 (2021).","journal-title":"Nat. Biotechnol."},{"key":"5778_CR64","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587 (2021).","journal-title":"Cell"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05778-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05778-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05778-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T07:08:41Z","timestamp":1681196921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-023-05778-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":64,"journal-issue":{"issue":"7952","published-print":{"date-parts":[[2023,3,16]]}},"alternative-id":["5778"],"URL":"https:\/\/doi.org\/10.1038\/s41586-023-05778-2","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,8]]},"assertion":[{"value":"15 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.M.T., R.G.M., M.C.R., L.L. and C.L.M. are inventors on a pending patent application\u00a0(PCT\/US2022\/017544, applicant: The Board of Trustees of the Leland Stanford Junior University) for the novel CARs described in this manuscript. R.G.M. and C.L.M. are co-founders of and hold equity in Link Cell Therapies. R.G.M., C.L.M. and L.L. are co-founders of and hold equity in Cargo Therapeutics (formerly\u00a0Syncopation Life Sciences). C.L.M. is a co-founder of and holds equity in Lyell Immunopharma. R.G.M., L.L. and E.W.W. are consultants for and hold equity in Lyell Immunopharma. S.P.R. is a former employee of and holds equity in Lyell Immunopharma. R.G.M. is a consultant for NKarta, Arovella Pharmaceuticals, Innervate Radiopharmaceuticals, GammaDelta Therapeutics, Aptorum Group, Zai Labs, Immunai, Gadeta, FATE Therapeutics (DSMB) and Waypoint Bio. A.T.S. is a founder of Immunai and Cartography Biosciences and receives research funding from Allogene Therapeutics and Merck Research Laboratories. C.L. is a consultant for Cartography Biosciences. A.M.T. and M.C.R. are consultants for and hold equity in Link Cell Therapies. A.M.T. is a consultant for and holds equity in Cargo Therapeutics (formerly\u00a0Syncopation Life Sciences). E.W.W. is a consultant for and holds equity in VISTAN Health and consults for Umoja Biopharma. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}